MNOV MediciNova, Inc.

5.57
+0  (3%)
Previous Close 5.43
Open 5.54
Price To book 5.43
Market Cap 192.32M
Shares 34,527,000
Volume 90,993
Short Ratio 69.57
Av. Daily Volume 40,377

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2b final data due 2H 2017.
MN-166
Progressive multiple sclerosis (progressive MS)
Phase 2 planned
MN-001
NASH (nonalcoholic steatohepatitis)
Phase 2 data released August 2014
MN-166
Opioid dependence
Phase 2 interim data released April 2016
MN-166
Amyotrophic lateral sclerosis (ALS)

Latest News

  1. MediciNova Announces Exploratory Interim Clinical Outcomes Data from Clinical Trial of MN-166 (ibudilast) in ALS Presented at the American Academy of Neurology (AAN) 69th Annual Meeting  in Boston
  2. MediciNova Announces MN-166 (ibudilast) Glioblastoma Abstract Selected for Presentation at the 2017 American Society of Clinical Oncology Annual Meeting in Chicago, Illinois
  3. MediciNova Announces MN-166 (ibudilast) Glioblastoma Abstract Selected for Presentation at the 5th Quadrennial Meeting of the World Federation of Neuro-Oncology Societies in Zurich, Switzerland
  4. MNOV: MN-166 Making Progress in Numerous Indications…
  5. MediciNova Announces MN-166 (ibudilast) ALS Abstract Accepted for Presentation at the American Academy of Neurology (AAN) 69th Annual Meeting in Boston
  6. MediciNova Announces Positive Findings from Completed Trial of MN-166 (ibudilast) in Methamphetamine Dependence Presented at the 50th Winter Conference on Brain Research
  7. MediciNova to Attend Mizuho Healthcare Conference in New York
  8. MNOV: Phase 2b Trial of MN-166 in Progressive MS Will Continue to Conclusion
  9. MediciNova, Inc. :MNOV-US: Earnings Analysis: Q3, 2016 By the Numbers : December 15, 2016
  10. MNOV: Interim Analysis of MN-166 in Progressive MS in 4Q16; ODD granted to MN-166 for ALS
  11. MediciNova, Inc. :MNOV-US: Earnings Analysis: Q2, 2016 By the Numbers : October 11, 2016
  12. MNOV: Interim Analysis For Phase 2b Trial of MN-166 in Progressive MS in 4Q16